<DOC>
	<DOC>NCT00099619</DOC>
	<brief_summary>This is a study with two treatment sequences and two treatment periods that will assess the safety and efficacy of exenatide treatment in patients with type 2 diabetes who have inadequate glycemic control using metformin or sulfonylurea and for whom insulin is the next appropriate step in diabetes treatment.</brief_summary>
	<brief_title>Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Main Treated with a stable dose of metformin or sulfonylurea for at least 3 months prior to screening. HbA1c between 7.1% and 11.0%, inclusive. Insulin therapy should be the next appropriate step of diabetes treatment. Body Mass Index (BMI) &gt;25 kg/m2 and &lt;40 kg/m2. Main Patient previously in a study involving exenatide or glucagonlike peptide1 analogs. Treated with insulin, thiazolidinediones, alphaglucosidase inhibitors, or meglitinides within 3 months prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>